News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Medicine Highlights Public Funding’s Role in Translating Scientific Discoveries into Life-Saving Treatments
Stephen Bagley, MD, MSCE, Assistant Professor of Hematology-Oncology and Neurosurgery at Penn Medicine, discusses how he used CAR T cell therapy to shrink a patient's tumor.
Nicholas Siciliano, Chief Executive Officer and Co-Founder of Penn Spinout ViTToria Biotherapeutics, Wins the Science Center’s 2025 Commercialization Award
Siciliano won the Science Center’s 2025 Commercialization Award in recognition of his outstanding contributions to the commercialization of innovative science and technology.
Avisi Technologies Present Promising Clinical Data at the American Glaucoma Society
Avisi is based on technology invented by Igor Bargatin, PhD, Associate Professor of Mechanical Engineering and Applied Mechanics at Penn Engineering.
Apellis’ Empaveli® Gains FDA Approval for Broader Rare Kidney Disease Use
Penn spinout Apellis received FDA approval for an expanded label for Empaveli®.
Carisma Therapeutics Enters into Definitive Merger Agreement with OrthoCellix to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Carisma Therapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine at Penn Medicine, is merging with OrthoCellix.
Jim Wilson’s Gemma Biotherapeutics Enters into Partnership with the Abu Dhabi Department of Health and Purehealth to Advance Global Access to Gene Therapies for Rare Diseases
Gemma plans to establish manufacturing and research centers in Abu Dhabi.
Lilly Acquires Verve Therapeutics to Advance One-time Treatments for People with High Cardiovascular Risk
Eli Lilly has acquired Verve Therapeutics, a startup co-founded by Kiran Musunuru.
Penn Spinout Dispatch Bio Emerges from Stealth Mode with $216M in Funding
Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a universal cancer treatment for solid tumors.
Penn Spinout Interius Therapeutics To Be Acquired by Kite Therapeutics for $350M
Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics .